Japan Professional Acne Medication Market Analysis

Name: Japan Professional Acne Medication Market Analysis
Creator: Next Move Strategy Consulting
Published: 2025-05-29T20:00:00-04:00
License: https://www.nextmsc.com/privacy-policy

About Report

Download Now

Japan Professional Acne Medication Market By Acne Type (Inflammatory Acne, Non-Inflammatory Acne), By Formulation (Topical Medications, Combination Treatments and Others), By Acne Severity (Mild, Moderate, Severe, Post-Inflammatory Hyperpigmentation), By Distribution Channel (Dermatologist & Aesthetician, Pharmacies & Drug Stores and Others), By End User (Dermatology Clinics, Hospitals & Healthcare Facilities and Others) – Analysis & Forecast, 2025–2035

Download PDF

Speak to Our Analyst

Industry Outlook

The Japan Professional Acne Medication Market size was valued at USD 182.14 million in 2025 and is expected to reach USD 198.70 million by 2026. Looking ahead, the industry is projected to expand steadily, reaching USD 283.23 million by 2035, registering a CAGR of 4.02% from 2026 to 2035.

The Japan professional acne medication market is shaped by precision, patience, and a strong preference for medically conservative care. Acne treatment is approached as a long-term skin condition, with professional medications introduced gradually and adjusted carefully to minimise irritation and maintain skin balance. Dermatologists emphasise regimen discipline and consistency, which supports steady use of prescription topicals and selectively prescribed oral therapies. Adult acne, particularly stress- and hormone-related cases, represents a significant share of demand, reflecting lifestyle and demographic trends. Patients tend to value safety, formulation quality, and predictable outcomes over rapid results, influencing prescribing behaviour and product choice. While market growth is measured rather than aggressive, it is highly stable, supported by strong healthcare access, high patient compliance, and deep trust in clinician-guided dermatological treatment.

Discipline-Oriented Skincare Culture Drives the Japan Professional Acne Medication Market Growth

In the Japan’s professional acne medication market, skincare is deeply rooted in discipline, routine, and prevention. Japanese consumers generally prioritise long-term skin balance over rapid corrective measures, viewing acne as a condition influenced by internal health, lifestyle regularity, and environmental exposure. This perspective encourages individuals to seek professional guidance when acne persists, rather than experimenting with multiple cosmetic products. Patients are willing to follow dermatologist-recommended regimens with high consistency, reflecting cultural values of patience and adherence. Adolescents, working professionals, and even older adults demonstrate a strong commitment to structured care, which supports steady demand for professional acne medications. The emphasis on maintaining clear, healthy skin as part of daily self-care reinforces acceptance of clinically supervised treatments that offer gradual yet reliable results.

Advanced Clinical Standards and Pharmaceutical Precision Drives Japan Professional Acne Medication Market Expansion

Japan’s healthcare system is characterised by meticulous clinical standards and pharmaceutical precision, which significantly influence acne treatment practices. Dermatologists typically prescribe medications within carefully defined protocols that emphasise safety, appropriate dosing, and long-term tolerability. Many acne therapies are supported by extensive clinical validation before widespread adoption, reinforcing patient trust in prescribed treatments. Japanese pharmaceutical companies are known for refining formulations to reduce irritation while maintaining efficacy, aligning with patient expectations for gentle yet effective care. Continuous collaboration between research institutions, hospitals, and clinics ensures that treatment approaches evolve steadily rather than abruptly. This precision-driven ecosystem sustains consistent prescription volumes and reinforces the role of professional acne medications as a core component of dermatological care in Japan.

Cautious Prescribing and Delayed Adoption of Innovations Acts as Japan Professional Acne Medication Market Restraints

A notable restraint in Japan professional acne medication market is the cautious approach toward adopting newer therapies. Physicians prefer established treatments with proven safety profiles, particularly when managing long-term or systemic acne cases. This conservative prescribing culture slows the introduction of innovative medications, even when global evidence supports their effectiveness. Patients, in turn, share similar caution, expressing concern about side effects or long-term skin impact. Treatment plans are typically escalated gradually, which extends therapy timelines and delays uptake of advanced options. While this approach ensures patient safety and trust, it moderates short-term market growth by lengthening adoption cycles for new professional acne medications.

Ultra-Gentle and Preventive Treatment Innovations Creates Japan Professional Acne Medication Market Opportunities

Japan offers strong growth potential for acne treatments that align with its preventive and skin-sensitive care philosophy. There is increasing demand for professional medications designed for daily, long-term use that support the skin barrier and minimise irritation. Innovations such as low-dose formulations, microbiome-friendly therapies, and maintenance-focused regimens resonate strongly with both patients and clinicians. Dermatologists are also placing greater emphasis on preventing acne recurrence rather than treating flare-ups alone. Products positioned around prevention, consistency, and skin harmony are likely to gain faster acceptance. As manufacturers tailor innovation to these preferences, professional acne medications achieve deeper market penetration and sustained growth in Japan.

Competitive Landscape

The Japan professional acne medication industry comprises various market players, such as Bioderma, AbbVie Inc., Kenvue Inc., Leo Pharma A/S, Pfizer Inc., Galderma S.A., Bayer AG, Sun Pharmaceutical Industries Ltd., Mentholatum Mexico, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline group of companies, Galderma S.A., La Roche-Posay, Orion Corporation, Viatris Inc and others.

Japan Professional Acne Medication Market Key Segments

By Acne Type

Inflammatory Acne
- Papules & Pustules
- Nodules
- Cystic Acne
Non-Inflammatory Acne
- Open Comedones
- Closed Comedones

By Formulation

Topical Medications
- Gels
- Creams
- Lotions
- Other Tropical Medications
Combination Treatments
Laser and Light-Based Treatments
- Blue Light Therapy
- Intense Pulsed Light
- Photodynamic Therapy
Oral Medications
- Tablets
- Capsules
- Oral Suspensions

By Acne Severity

Mild Acne
Moderate Acne
Severe Acne
Post-Inflammatory Hyperpigmentation (Pih)

By Skin Type

Normal/Combination Skin
Dry Skin
Oily Skin
Sensitive Skin

By Age Group

Pediatric Patients (≤12 years)
Teenagers and Young Adults (13-30 years)
Adults (31 years and Above)

By Therapeutic Class

Retinoids
Antibiotics
Salicylic Acid
Benzoyl Peroxide
Others

By Price Tier

Low Price Tier
Mid Price Tier
High Price Tier

By Treatment Setting

In-Clinic / In-Office Treatment
At-Home Treatment
Hybrid Treatment Model

By Application

Facial Acne Treatment
Body Acne Treatment
Scalp Acne Treatment

By Distribution Channel

Dermatologist & Aesthetician
Pharmacies & drug store
E-Commerce
Others

By End User

Dermatology Clinics
Hospitals & Healthcare Facilities
Medical Spas
Cosmetic Surgeons
Pharmacies / Chemists
Teledermatology Services
Other End Users

Key Players

Bioderma
AbbVie Inc.
Kenvue Inc.
Leo Pharma A/S
Pfizer Inc
Galderma S.A.
Bayer AG
Sun Pharmaceutical Industries Ltd.
Mentholatum Mexico
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline group of companies
Galderma S.A.
La Roche-Posay
Orion Corporation
Viatris Inc.

Report Scope and Segmentation:

Parameters	Details
Market Size in 2026	USD 198.70 Million
Revenue Forecast in 2035	USD 283.23 Million
Growth Rate	CAGR of 4.02% from 2026 to 2035
Analysis Period	2025–2035
Base Year Considered	2025
Forecast Period	2026–2035
Market Size Estimation	Million (USD)
Growth Factors	Discipline-Oriented Skincare Culture Driving Medical Adoption Advanced Clinical Standards and Pharmaceutical Precision
Companies Profiled	15
Market Share	Available for 10 companies
Customization Scope	Free customization (equivalent to up to 80 analyst-working hours) after purchase. Addition or alteration to country, regional & segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.
Approach	In-depth primary and secondary research; proprietary databases; rigorous quality control and validation measures.
Analytical Tools	Porter's Five Forces, SWOT, value chain, and Harvey ball analysis to assess competitive intensity, stakeholder roles, and relative impact of key factors.

About the Author

Saista Faiyaz is a Research Associate specializing in analytical research, structured data review, and knowledge-driven insight development. She supports projects through methodical evaluation, cross-disciplinary understanding, and clear documentation that aid informed outcomes. With experience bridging research and technical domains, she contributes to organized learning processes, critical analysis, and collaborative problem solving. Her approach emphasizes accuracy, adaptability, and clarity, enabling consistent research support and meaningful contributions across diverse projects effectively.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2023 - 2030, MILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 DRIVER 1
  2. 5.1.2 DRIVER 2
  3. 5.1.3 DRIVER 3
  4. 5.1.4 DRIVER 4
3. 5.2 CHALLENGES
4. 1. 5.2.1 CHALLENGE 1
  2. 5.2.2 CHALLENGE 2
  3. 5.2.3 CHALLENGE 3
  4. 5.2.4 CHALLENGE 4
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 OPPORTUNITY 1
  2. 5.3.2 OPPORTUNITY 2

1. 6.1 OVERVIEW
2. 6.2 INFLAMMATORY ACNE MARKET
3. 6.3 NON-INFLAMMATORY ACNE MARKET

1. 7.1 OVERVIEW
2. 7.2 TOPICAL MEDICATIONS MARKET
3. 7.3 ORAL MEDICATIONS MARKET

1. 8.1 OVERVIEW
2. 8.2 RETINOIDS MARKET
3. 8.3 ANTIBIOTICS MARKET
4. 8.4 SALICYLIC ACID MARKET
5. 8.5 BENZOYL PEROXIDE MARKET
6. 8.6 OTHERS MARKET

1. 9.1 OVERVIEW
2. 9.2 MED SPA MARKET
3. 9.3 AESTHETICIAN MARKET
4. 9.4 DERMATOLOGIST MARKET
5. 9.5 OTHER PROFESSIONAL CHANNELS MARKET

1. 10.1 ALMIRALL S.A.
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 BAUSCH HEALTH COMPANIES, INC.
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 GLAXOSMITHKLINE PLC (GSK)
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 GALDERMA S.A.
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 SUN PHARMACEUTICAL INDUSTRIES LIMITED
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS
13. 10.7 JOHNSON AND JOHNSON
14. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
15. 10.8 ELI LILLY AND COMPANY
16. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
17. 10.9 MYLAN N.V.
18. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
19. 10.10 DAIICHI SANKYO COMPANY, LTD
20. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS

TABLE 1. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)
TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 4. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)
TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 6. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 7. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)
TABLE 8. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 9. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 10. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 12. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 13. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)
TABLE 14. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 15. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 16. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)
TABLE 18. BAYER AG: COMPANY SNAPSHOT
TABLE 19. BAYER AG: OPERATING BUSINESS SEGMENTS
TABLE 20. BAYER AG: PRODUCT PORTFOLIO
TABLE 21. BAYER AG: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 22. BAYER AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 23. BAYER AG: KEY STRATERGY
TABLE 24. NESTLE S.A.: COMPANY SNAPSHOT
TABLE 25. NESTLE S.A.: OPERATING BUSINESS SEGMENTS
TABLE 26. NESTLE S.A.: PRODUCT PORTFOLIO
TABLE 27. NESTLE S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 28. NESTLE S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 29. NESTLE S.A.: KEY STRATERGY
TABLE 30. PFIZER INC.: COMPANY SNAPSHOT
TABLE 31. PFIZER INC.: OPERATING BUSINESS SEGMENTS
TABLE 32. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 33. PFIZER INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 34. PFIZER INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 35. PFIZER INC.: KEY STRATERGY
TABLE 36. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 37. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS
TABLE 38. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 39. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 40. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 41. JOHNSON AND JOHNSON: KEY STRATERGY
TABLE 42. ROCHE HOLDING AG: COMPANY SNAPSHOT
TABLE 43. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS
TABLE 44. ROCHE HOLDING AG: PRODUCT PORTFOLIO
TABLE 45. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 46. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 47. ROCHE HOLDING AG: KEY STRATERGY
TABLE 48. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 49. GLAXOSMITHKLINE PLC: OPERATING BUSINESS SEGMENTS
TABLE 50. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 51. GLAXOSMITHKLINE PLC: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 52. GLAXOSMITHKLINE PLC: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 53. GLAXOSMITHKLINE PLC: KEY STRATERGY
TABLE 54. GALDERMA S.A.: COMPANY SNAPSHOT
TABLE 55. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS
TABLE 56. GALDERMA S.A.: PRODUCT PORTFOLIO
TABLE 57. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 58. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 59. GALDERMA S.A.: KEY STRATERGY
TABLE 60. ALLERGAN PLC: COMPANY SNAPSHOT
TABLE 61. ALLERGAN PLC: OPERATING BUSINESS SEGMENTS
TABLE 62. ALLERGAN PLC: PRODUCT PORTFOLIO
TABLE 63. ALLERGAN PLC: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 64. ALLERGAN PLC: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 65. ALLERGAN PLC: KEY STRATERGY
TABLE 66. STIEFEL LABORATORIES INC.: COMPANY SNAPSHOT
TABLE 67. STIEFEL LABORATORIES INC.: OPERATING BUSINESS SEGMENTS
TABLE 68. STIEFEL LABORATORIES INC.: PRODUCT PORTFOLIO
TABLE 69. STIEFEL LABORATORIES INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 70. STIEFEL LABORATORIES INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 71. STIEFEL LABORATORIES INC.: KEY STRATERGY
TABLE 72. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 73. BAUSCH HEALTH COMPANIES INC.: OPERATING BUSINESS SEGMENTS
TABLE 74. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 75. BAUSCH HEALTH COMPANIES INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 76. BAUSCH HEALTH COMPANIES INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 77. BAUSCH HEALTH COMPANIES INC.: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)
FIGURE 7. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 9. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)
FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 11. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 12. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)
FIGURE 13. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 14. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 15. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 17. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 18. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)
FIGURE 19. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 20. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 21. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)
FIGURE 23. BAYER AG: NET SALES, (2021-2023)
FIGURE 24. BAYER AG: PRIMARY MARKET COMPETITORS
FIGURE 25. NESTLE S.A.: NET SALES, (2021-2023)
FIGURE 26. NESTLE S.A.: PRIMARY MARKET COMPETITORS
FIGURE 27. PFIZER INC.: NET SALES, (2021-2023)
FIGURE 28. PFIZER INC.: PRIMARY MARKET COMPETITORS
FIGURE 29. JOHNSON AND JOHNSON: NET SALES, (2021-2023)
FIGURE 30. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS
FIGURE 31. ROCHE HOLDING AG: NET SALES, (2021-2023)
FIGURE 32. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS
FIGURE 33. GLAXOSMITHKLINE PLC: NET SALES, (2021-2023)
FIGURE 34. GLAXOSMITHKLINE PLC: PRIMARY MARKET COMPETITORS
FIGURE 35. GALDERMA S.A.: NET SALES, (2021-2023)
FIGURE 36. GALDERMA S.A.: PRIMARY MARKET COMPETITORS
FIGURE 37. ALLERGAN PLC: NET SALES, (2021-2023)
FIGURE 38. ALLERGAN PLC: PRIMARY MARKET COMPETITORS
FIGURE 39. STIEFEL LABORATORIES INC.: NET SALES, (2021-2023)
FIGURE 40. STIEFEL LABORATORIES INC.: PRIMARY MARKET COMPETITORS
FIGURE 41. BAUSCH HEALTH COMPANIES INC.: NET SALES, (2021-2023)
FIGURE 42. BAUSCH HEALTH COMPANIES INC.: PRIMARY MARKET COMPETITOR

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The key market players operating in the Japan professional acne medication market are Bioderma, AbbVie Inc., Kenvue Inc., Leo Pharma A/S, Pfizer Inc., Galderma S.A., and others.

According to the report published by Next Move Strategy Consulting, Japan professional acne medication market is valued at USD 198.70 Million in 2026.

According to Next Move Strategy Consulting, the market size is estimated to be USD 283.23 Million by 2035.

Japan reflects a precision-led healthcare culture, where acne treatments are selected for safety, consistency, and long-term skin health rather than rapid results.

Prescribing patterns favor gradual, sustained therapy use, resulting in stable demand built on trust in dermatologist guidance and regulated treatment pathways.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Purchase Options Flash
sale

Multi User

$3,217 $4595

Single User

$2,517 $3595

Enterprise

$4,617 $6595

Datapack

$1,467 $2095

Download Sample

Inquire Before Buying

Speak to Our Analyst

Share with Peers

Request Sample